Skip to main content

Proactive news headlines including Spenda Ltd, Island Pharmaceuticals, Tempus Resources and Paradigm Biopharmaceuticals

Written by Customer Service on . Posted in Mergers And Acquisitions.

Sydney, Dec. 28, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

  • Spenda Ltd (ASX:SPX) and Fiserv have entered into a two-year Payment Facilitator agreement, whereby Fiserv will provide direct merchant facilities to Spenda’s customers. Click here
  • Island Pharmaceuticals Ltd (ASX:ILA), an Australian mid-clinical stage antiviral drug development company, has submitted an Investigational New Drug (IND) application for the ISLA-101 Phase 2a PEACH clinical trial. Click here
  • Tempus Resources Ltd (ASX:TMR, TSX-V:TMRR) has boosted its finances to the tune of C$680,100 (~A$747,939) after completing a non-brokered private placement. Click here
  • Paradigm Biopharmaceuticals Ltd (ASX:PAR) announced today that the first safety review meeting of the Data Monitoring Committee (DMC) for the pivotal PARA_OA_002 clinical trial was conducted on December 20. Click here

About Proactive

  • Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • With six offices on three continents, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives to engage intelligently with investors.
  • In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites. Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006. 

For more information on how Proactive can help you make a difference, email us at action@proactiveinvestors.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.